Technical Evaluation and Results of the Use of TREO® Modular Aortic Endografts for the Treatment of Abdominal Aortic Aneurysms

Inclusion criteria

• Patient who has confirmed his/her non-opposition to the use of his/her data in the study.
• Patient aged 45 years or older.
• Patient with AAA with one of the following criteria:

• Maximum diameter ≥50 mm for women and ≥55 mm for men
• Rapid growth (≥5 mm in 6 months or ≥10 mm in 12 months)
• Unruptured AAA with clinical symptoms of abdominal pain
• Adequate anatomy for TREO® stent graft implantation, including:

• Adequate iliac and femoral arteries for the modular system
• Suprarenal angle less than 45 degrees
• Infrarenal aortic neck greater than or equal to 10 mm in length with an angle less than 60° and an internal diameter of 17mm-32mm, or an infrarenal aortic neck greater than or equal to 15 mm in length with an angle between 60 and 75° and an internal diameter of 16mm-30mm
• Distal iliac sealing distance ≥ 10 mm and an iliac diameter between 8-13 mm or a distal iliac sealing distance ≥ 15 mm and a diameter between 13-21 mm
• Ability to follow the entire protocol from 1 to 60 months
• Life expectancy greater than 2 years

Exclusion criteria

• Patients refusing treatment and follow-up as part of the study
• Infected or ruptured aneurysm
• Associated aortic lesion (thoracic or thoracoabdominal aneurysm) requiring management
• Renal failure defined by creatinine > 2.5 mg/dL or patient in pre-dialysis status and impossibility of intervention with use of CO2 injection
• New York Heart Association (NYHA) class IV
• Aneurysmal, dissected distal implantation zone, or including calcifications and/or significant thrombus that could compromise sealing
• Tortuous iliac and/or femoral access and/or including calcified stenosis
• Systemic infection that could increase the risk of infection of the endoprosthesis
• Pathology of the supporting tissues such as collagenosis (Marfan or Ehler-Danlos, etc.)
• Known drug use
• Known sensitivity or allergy to the materials to be implanted
• Patients contraindicated for antiplatelet treatment
• Patients with an uncontrolled hematological disorder or heparin-induced thrombocytopenia
• Patients who are pregnant or planning to become pregnant
• Patients considered hemodynamically unstable or requiring emergency treatment
• Patients with severe arterial disease leading to a negative "outflow" that may degrade the permeability of implanted stents
• Scheduled hybrid aortic technique (surgical and endovascular)
• Patients with complex iliac access outside the manufacturer's indications and recommendations that may lead to procedural failure